PH12015502129A1 - Methods for treating psoriasis using an anti-il-23 antibody - Google Patents
Methods for treating psoriasis using an anti-il-23 antibodyInfo
- Publication number
- PH12015502129A1 PH12015502129A1 PH12015502129A PH12015502129A PH12015502129A1 PH 12015502129 A1 PH12015502129 A1 PH 12015502129A1 PH 12015502129 A PH12015502129 A PH 12015502129A PH 12015502129 A PH12015502129 A PH 12015502129A PH 12015502129 A1 PH12015502129 A1 PH 12015502129A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibody
- methods
- treating psoriasis
- products
- psoriasis
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 230000001174 ascending effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789777P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/018293 WO2014149425A1 (en) | 2013-03-15 | 2014-02-25 | Methods for treating psoriasis using an anti-il-23 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502129A1 true PH12015502129A1 (en) | 2016-01-25 |
Family
ID=50336511
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502129A PH12015502129A1 (en) | 2013-03-15 | 2015-09-15 | Methods for treating psoriasis using an anti-il-23 antibody |
| PH12019502700A PH12019502700A1 (en) | 2013-03-15 | 2019-11-28 | Methods for treating psoriasis using an anti-il-23 antibody |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019502700A PH12019502700A1 (en) | 2013-03-15 | 2019-11-28 | Methods for treating psoriasis using an anti-il-23 antibody |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160060337A1 (enExample) |
| EP (2) | EP2968488A1 (enExample) |
| JP (4) | JP2016517408A (enExample) |
| KR (1) | KR20150128858A (enExample) |
| CN (1) | CN105209064A (enExample) |
| AP (1) | AP2015008803A0 (enExample) |
| AU (3) | AU2014238148A1 (enExample) |
| CA (1) | CA2906382A1 (enExample) |
| CL (1) | CL2015002723A1 (enExample) |
| CR (1) | CR20150572A (enExample) |
| EA (1) | EA201591581A1 (enExample) |
| HK (1) | HK1219425A1 (enExample) |
| IL (2) | IL241342A0 (enExample) |
| PH (2) | PH12015502129A1 (enExample) |
| SG (2) | SG10201804954UA (enExample) |
| TN (1) | TN2015000403A1 (enExample) |
| WO (1) | WO2014149425A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2635601B1 (en) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| WO2013165791A1 (en) | 2012-05-03 | 2013-11-07 | Boehringer Ingelheim International Gmbh | Anti-il-23p19 antibodies |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| US10059763B2 (en) | 2014-09-03 | 2018-08-28 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and TNF-alpha and uses thereof |
| IL307578A (en) * | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| US10765724B2 (en) * | 2016-03-29 | 2020-09-08 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody |
| AU2017250583A1 (en) * | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| JP7634474B2 (ja) * | 2018-07-18 | 2025-02-21 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子 |
| KR20210091209A (ko) * | 2018-11-05 | 2021-07-21 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 항-tigit 항체의 투여 요법 |
| EP3941934A4 (en) * | 2019-03-18 | 2022-12-07 | Janssen Biotech, Inc. | METHODS OF TREATMENT OF PSORIASIS IN CHILDREN WITH ANTI-IL12/IL23 ANTIBODIES |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
| ES2410406T3 (es) | 2005-06-30 | 2013-07-01 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
| EP1937721B1 (en) | 2005-08-25 | 2010-07-28 | Eli Lilly And Company | Anti-il-23 antibodies |
| US20070050011A1 (en) | 2005-08-26 | 2007-03-01 | Medlogics Device Corporation | Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs |
| HUE032131T2 (en) | 2005-08-31 | 2017-09-28 | Merck Sharp & Dohme | Constructed anti-IL-23 antibodies |
| AU2006330410A1 (en) * | 2005-12-28 | 2007-07-05 | Centocor, Inc. | Markers and methods for assessing and treating psoriasis and related disorders |
| EP3219328B1 (en) | 2005-12-29 | 2020-06-17 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, method and uses |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| EP2064242A1 (en) * | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| ATE554791T1 (de) | 2007-02-23 | 2012-05-15 | Schering Corp | Gentechnisch hergestellte anti-il-23p19- antikörper |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US8557239B2 (en) * | 2009-09-14 | 2013-10-15 | Abbvie Inc. | Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23 |
| TWI461210B (zh) * | 2008-03-18 | 2014-11-21 | Abbvie Inc | 治療牛皮癬的方法 |
| WO2010002776A2 (en) | 2008-06-30 | 2010-01-07 | Black & Decker Inc. | Cord protector for power tools |
| WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| WO2010115786A1 (en) | 2009-04-01 | 2010-10-14 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2011088120A1 (en) | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
| US9127057B2 (en) | 2010-07-20 | 2015-09-08 | Teva Pharmaceuticals Ausralia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
| CN103813804A (zh) * | 2010-10-06 | 2014-05-21 | Abbvie公司 | 用于治疗银屑病的方法 |
| CN103154031A (zh) * | 2010-10-08 | 2013-06-12 | 诺华有限公司 | 利用il-17拮抗剂治疗牛皮癣的方法 |
| EP2635601B1 (en) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
-
2014
- 2014-02-25 US US14/776,222 patent/US20160060337A1/en not_active Abandoned
- 2014-02-25 AP AP2015008803A patent/AP2015008803A0/xx unknown
- 2014-02-25 JP JP2016500381A patent/JP2016517408A/ja active Pending
- 2014-02-25 HK HK16107479.7A patent/HK1219425A1/zh unknown
- 2014-02-25 EA EA201591581A patent/EA201591581A1/ru unknown
- 2014-02-25 CA CA2906382A patent/CA2906382A1/en not_active Abandoned
- 2014-02-25 CN CN201480015797.0A patent/CN105209064A/zh active Pending
- 2014-02-25 WO PCT/US2014/018293 patent/WO2014149425A1/en not_active Ceased
- 2014-02-25 EP EP14711352.6A patent/EP2968488A1/en not_active Withdrawn
- 2014-02-25 AU AU2014238148A patent/AU2014238148A1/en not_active Abandoned
- 2014-02-25 SG SG10201804954UA patent/SG10201804954UA/en unknown
- 2014-02-25 EP EP19206477.2A patent/EP3689369A1/en not_active Withdrawn
- 2014-02-25 SG SG11201507482UA patent/SG11201507482UA/en unknown
- 2014-02-25 KR KR1020157027833A patent/KR20150128858A/ko not_active Ceased
-
2015
- 2015-09-09 TN TN2015000403A patent/TN2015000403A1/en unknown
- 2015-09-09 IL IL241342A patent/IL241342A0/en unknown
- 2015-09-15 CL CL2015002723A patent/CL2015002723A1/es unknown
- 2015-09-15 PH PH12015502129A patent/PH12015502129A1/en unknown
- 2015-10-15 CR CR20150572A patent/CR20150572A/es unknown
-
2019
- 2019-01-11 AU AU2019200206A patent/AU2019200206A1/en not_active Abandoned
- 2019-09-24 JP JP2019172758A patent/JP2020063237A/ja active Pending
- 2019-10-10 US US16/598,714 patent/US20200277368A1/en not_active Abandoned
- 2019-11-28 PH PH12019502700A patent/PH12019502700A1/en unknown
-
2020
- 2020-06-03 IL IL275093A patent/IL275093A/en unknown
- 2020-11-18 AU AU2020270495A patent/AU2020270495A1/en not_active Abandoned
-
2021
- 2021-03-29 JP JP2021054632A patent/JP2021102644A/ja active Pending
-
2022
- 2022-01-13 US US17/574,980 patent/US20220135668A1/en not_active Abandoned
- 2022-11-02 JP JP2022175999A patent/JP2023011815A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150572A (es) | 2016-04-25 |
| WO2014149425A1 (en) | 2014-09-25 |
| CL2015002723A1 (es) | 2016-03-28 |
| EP3689369A1 (en) | 2020-08-05 |
| US20220135668A1 (en) | 2022-05-05 |
| PH12019502700A1 (en) | 2020-12-07 |
| TN2015000403A1 (en) | 2017-01-03 |
| CN105209064A (zh) | 2015-12-30 |
| AU2014238148A1 (en) | 2015-10-08 |
| EA201591581A1 (ru) | 2016-01-29 |
| EP2968488A1 (en) | 2016-01-20 |
| SG10201804954UA (en) | 2018-07-30 |
| US20200277368A1 (en) | 2020-09-03 |
| JP2016517408A (ja) | 2016-06-16 |
| JP2021102644A (ja) | 2021-07-15 |
| SG11201507482UA (en) | 2015-10-29 |
| US20160060337A1 (en) | 2016-03-03 |
| AP2015008803A0 (en) | 2015-10-31 |
| KR20150128858A (ko) | 2015-11-18 |
| IL275093A (en) | 2020-07-30 |
| IL241342A0 (en) | 2015-11-30 |
| JP2023011815A (ja) | 2023-01-24 |
| AU2019200206A1 (en) | 2019-01-31 |
| HK1219425A1 (zh) | 2017-04-07 |
| AU2020270495A1 (en) | 2020-12-17 |
| JP2020063237A (ja) | 2020-04-23 |
| CA2906382A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502700A1 (en) | Methods for treating psoriasis using an anti-il-23 antibody | |
| PH12015502133A1 (en) | Methods for treating crohn's disease using an anti-il23 antibody | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
| MX2017007321A (es) | Terapias de combinacion. | |
| NZ715201A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| ES2681973T3 (es) | Respuesta antitumoral contra autoepítopos modificados | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| MX2017001638A (es) | Molecula portadora para antigenos. | |
| PH12021551111A1 (en) | Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk | |
| BR112017014994A2 (pt) | formulação em pó nasal para o tratamento de hipoglicemia | |
| MX2022005469A (es) | Combinaciones de dosis fija y formulaciones que comprenden acido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y metodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
| MY199248A (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| PH12017501930A1 (en) | Calicheamicin contructs and methods of use | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| BR112016002619A2 (pt) | moléculas de ligação do receptor de bag3 para o uso como um medicamento |